EDI-OCT and CVI findings can shed light on choroidal vascular physiology following COVID-19 pneumonia

News
Article

Investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography

Images of a chest X-ray and a CT scan show the chest and vascular system following a COVID-19 infection. Image credit: ©samunella – stock.adobe.com

The patients who had recovered from COVID-19 pneumonia had significantly higher values in the mean total choroidal area, the stromal area and the luminal area. Image credit: ©samunella – stock.adobe.com

Researchers from Istanbul, Turkey, conducted a study that found that the choroidal vascularity index (CVI) can shed light on the choroidal vascular physiology in patients who had had mild COVID-19 pneumonia and recovered completely,1 reported Muge Toprak, MD, and colleagues. Toprak is from the Kocaeli City Hospital, Istanbul. They published their findings in International Ophthalmology.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia (group one, COVID group) were included along with 45 healthy individuals (group two, healthy control group).

All fully recovered patients were evaluated 6 months after the pneumonia resolved. The investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography (EDI-OCT). The primary measurement of interest was the CVI, which the investigators defined as the ratio of the luminal area to the total choroidal area.

The patients who comprised group one (COVID group) had significantly higher values compared to the healthy group two controls in the mean total choroidal area, the stromal area and the luminal area. There was no difference in the CVI between the two groups (P = 0.080).

Based on their findings, the investigators concluded that the CVI can reveal the choroidal vascular physiology in patients who have fully recovered from COVID-19 pneumonia. The EDI-OCT technology can be used to evaluate choroidal vascular alterations and thereby serve as a non-invasive indicator for early vascular impairment following SARS-CoV-2 infection.

Reference

1. Toprak M, Kesim E, Karasu B, Celebi ARC. Choroidal vascularity index findings in patients recovered from mild course COVID-19 pneumonia.Int Ophthalmol. 2025;45:84. https://doi.org/10.1007/s10792-025-03450-4

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.